September 1, 2015 — CP3 Co-Director Walid Gellad, MD, MPH authored a viewpoint in JAMA describing the efficacy and safety of flibanserin for female hypoactive sexual desire disorder (HSDD). Dr. Gellad was a member of the FDA panel that reviewed data on the medication on June 4, 2015. Read more »